HONG KONG – Even as Asian markets wobble and investors scrutinize every move, Chinese drugmaker Yichang HEC Changjiang Pharmaceutical Co. Ltd., which focuses on developing, manufacturing and selling antiviral medicines, launched an IPO in Hong Kong Monday looking to raise as much as HK$1.67 billion (US$215 million).